SPOTLIGHT: Adherex inks deal with GSK

Adherex Technologies of Research Triangle Park, North Carolina, has inked a deal in-licensing GSK's oncology product eniluracil -- with GSK retaining an option to buy it back -- and giving GSK an option to license Adherex's lead biotechnology compound, ADH-1. GSK also made a $3 million equity investment in Adherex. GSK's options in the deal could be collectively worth up to $220 million in milestones plus royalties. Release

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.